NTU Singapore study investigates link between COVID-19 and risk of blood clot formation eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
She sleeps early, exercises regularly, and never smokes or drinks, yet Chan Sik Mun was diagnosed with Stage 4 non-small cell lung cancer (NSCLC) in November 2014. And she was only age 55.
The dreaded ailment seemingly came out of nowhere and hit the former banker squarely in her chest, and literally took the wind out of her.
Feeling something was wrong
The only hint that something was wrong was how Chan felt winded when she barely even made it up half a flight of stairs to cross the overhead bridge.
This was unusual for someone as active, lean, and spritely as her, she thought.
Elixir Medical’s 24-Month Clinical Results for DynamX Bioadaptor Showed Strong Safety Profile, With No Clinical Events
January 28, 2021
The DynamX Bioadaptor is a new class of treatment for Coronary Artery Disease.
SINGAPORE, January 28, 2021 /EINPresswire.com/ Elixir Medical’s 24-Month Clinical Results for DynamX Bioadaptor Showed Strong Safety Profile, With No Clinical Events
Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, recently presented at 30th Annual Live Interventions in Vascular Endotherapy conference organised by the National Heart Centre of Singapore (Singapore LIVE). The bioadaptor is the first coronary artery implant that adapts to vessel physiology.
Bayer, National Heart Center Singapore to develop explorative cardiovascular center
By Anh Nguyen December 22, 2020 | 04:43 pm GMT+7
Bayer and National Heart Center Singapore (NHCS) announced they had inked a five-year agreement to develop a “Center of Excellence for Explorative Cardiovascular Studies.”
The center aims to boost patient-centricity in research and development (R&D) and improve treatment outcomes in cardiovascular disease (CVD) management.
Combining NHCS’s vast experience in managing Asian CVD patients and clinical research with Bayer’s expertise in pharmaceutical R&D, the center will generate and integrate high quality patient data into early clinical research that would allow better understanding of the underlying biology of CVDs. Results could potentially lead to future targeted therapies to address unmet medical needs in defined patient populations. Bayer will contribute S$5.4 million ($4 million) towards the setup of the center.
Bayer and NHCS to set up Center of Excellence for Explorative Cardiovascular Studies vir.com.vn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vir.com.vn Daily Mail and Mail on Sunday newspapers.